Prognostic significance of K- ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with dukes C colon cancer

2001 ◽  
Vol 44 (3) ◽  
pp. 358-363 ◽  
Author(s):  
W. A. Bleeker ◽  
V. M. Hayes ◽  
A. Karrenbeld ◽  
R. M. W. Hofstra ◽  
E. Verlind ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Prognostic Significance ◽  
Tp53 Mutations ◽  
Dukes C

Choroid plexus tumours

2019 ◽  
pp. 403-410
Author(s):  
Jonathan Roth ◽  
Rina Dvir ◽  
Shlomi Constantini
Keyword(s):  
Early Childhood ◽  
Adjuvant Chemotherapy ◽  
Choroid Plexus ◽  
Surgical Excision ◽  
Complete Resection ◽  
Tp53 Mutations ◽  
Pathological Subtypes

Choroid plexus tumours (CPT) are relatively rare and include three pathological subtypes: papilloma (CPP) (benign); carcinoma (CPC) (malignant); atypical papilloma (ACPP) (intermediate). Most cases of CPT occur during early childhood and infancy; however, occurrence at all paediatric ages as well as adulthood has been documented. The main treatment of CPT is surgical, aiming for complete resection in all subtypes of CPT. The location and vascularity of CPT present a special surgical challenge. Surgical excision of CPP can be curative. In the malignant CPC form, adjuvant chemotherapy is indicated. The role of radiotherapy is controversial. A subset of patients with CPT harbour germline or somatic TP53 mutations characterized by greater tumour aggressiveness and decreased survival.

scholarly journals Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy

JAMA Oncology ◽  
2018 ◽  
Vol 4 (3) ◽  
pp. 379 ◽  
Author(s):  
Aziz Zaanan ◽  
Qian Shi ◽  
Julien Taieb ◽  
Steven R. Alberts ◽  
Jeffrey P. Meyers ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Mismatch Repair ◽  
Dna Mismatch Repair ◽  
Stage Iii ◽  
Dna Mismatch ◽  
Stage Iii Colon Cancer ◽  
Mismatch Repair Status

Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer

2000 ◽  
Vol 95 (10) ◽  
pp. 2953-2957 ◽  
Author(s):  
W.A. Bleeker ◽  
V.M. Hayes ◽  
A. Karrenbeld ◽  
R.M.W. Hofstra ◽  
J. Hermans ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Tp53 Mutations ◽  
Left And Right ◽  
Dukes C

The role of adjuvant chemotherapy in stage II and III mucinous colon cancer

2019 ◽  
Vol 120 (7) ◽  
pp. 1190-1200 ◽  
Author(s):  
Adam C. Fields ◽  
Pamela Lu ◽  
Joel Goldberg ◽  
Jennifer Irani ◽  
Ronald Bleday ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Stage Ii

Prognostic Significance of CEA and CA 19–9 inc Colorectal Cancer in Kuwait

2000 ◽  
Vol 15 (1) ◽  
pp. 51-55 ◽  
Author(s):  
A.I. Behbehani ◽  
H. Al-Sayer ◽  
M. Farghaly ◽  
N. Kanawati ◽  
A. Mathew ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Chemotherapy ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Prognostic Indicators ◽  
Chi Square ◽  
Free Survival ◽  
Significant Difference ◽  
Disease Free ◽  
Dukes C

Preoperative CEA and CA 19–9 levels have been used in the past as prognostic indicators in colorectal cancer, but Dukes’ stage is still considered to be the most important prognostic factor. Recent survival estimates may have been influenced by the fact that in the last decade adjuvant chemotherapy and postoperative irradiation have been included in the routine management of advanced-stage disease. In a heterogeneous Kuwaiti population higher reference levels (95th percentile) of CEA and CA 19–9 have been found than those usually employed. In the present study 62 patients with Dukes’ stage B + C could be analyzed for two-year disease-free survival (DFS). Relapse was observed in 19 patients, 28 patients were disease free and 15 patients with censored observations were included. No significant difference in DFS was observed in Dukes’ B (69%) versus Dukes’ C (48%) patients (p=0.09). On the other hand, Dukes’ stage B+C patients with elevated preoperative levels of CEA or CA 19–9 had a significantly poorer DFS than patients with normal levels. For CEA levels below or above the cutoff the DFS was 74% versus 23% (p=0.003); for CA 19–9 levels below or above the cutoff the DFS was 71% versus 33% (p=0.004). In 54 patients with Dukes’ stage B+C for whom preoperative levels of both CEA and CA 19–9 were available multivariate analysis revealed a decreasing risk of relapse in the following order: CEA and/or CA 19–9 elevated (chi-square 7.09; p=0.008), CA 19–9 elevated (chi-square 6.27; p=0.01), CEA elevated (chi-square 5.47; p=0.02), and Dukes’ C (chi-square 2.08; p=0.15 n.s.). Hence, novel treatment protocols may have improved the disease-free survival, but the use of adjuvant chemotherapy and/or radiotherapy is of questionable benefit in patients who have elevated levels of CEA and/or CA 19–9 prior to treatment.

Sign in / Sign up

Export Citation Format

Share Document